Prelude Therapeutics
$2.03
19
+$0.18+9.73% Monday 21:00
Statistics
Day High
2.07
Day Low
1.85
52W High
4.22
52W Low
0.61
Volume
119,249
Avg. Volume
1,546,634
Mkt Cap
85.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MarExpected
Expected EPS
-0.03
Actual EPS
N/A
Financials
-1,816.76%Profit Margin
Unprofitable14MRevenue
-254.35MNet Income
Analyst Ratings
$4.00Average Price Target
The highest estimate is 5.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 50%
Hold 50%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PRLD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
AMGEN
AMGN
Mkt Cap160.66B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
About
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Show more...
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Employees
131
Country
US
ISIN
US74065P1012
Listings
0 Comments
Share your thoughts
FAQ
What is Prelude Therapeutics stock price today?▼
The current price of PRLD is $2.03 USD — it has increased by +9.73% in the past 24 hours. Watch Prelude Therapeutics stock price performance more closely on the chart.
What is Prelude Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Prelude Therapeutics stocks are traded under the ticker PRLD.
Is Prelude Therapeutics stock price growing?▼
PRLD stock has fallen by -4.25% compared to the previous week, the month change is a -25.64% fall, over the last year Prelude Therapeutics has showed a +82.88% increase.
What is Prelude Therapeutics market cap?▼
Today Prelude Therapeutics has the market capitalization of 85.87M
When is the next Prelude Therapeutics earnings date?▼
Prelude Therapeutics is going to release the next earnings report on March 18, 2026.
What were Prelude Therapeutics earnings last quarter?▼
PRLD earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.37 USD resulting in a +29.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prelude Therapeutics revenue for the last year?▼
Prelude Therapeutics revenue for the last year amounts to 14M USD.
What is Prelude Therapeutics net income for the last year?▼
PRLD net income for the last year is -254.35M USD.
How many employees does Prelude Therapeutics have?▼
As of February 03, 2026, the company has 131 employees.
In which sector is Prelude Therapeutics located?▼
Prelude Therapeutics operates in the Health Care sector.
When did Prelude Therapeutics complete a stock split?▼
Prelude Therapeutics has not had any recent stock splits.
Where is Prelude Therapeutics headquartered?▼
Prelude Therapeutics is headquartered in Wilmington, US.